Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ESLA
stocks logo

ESLA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Estrella Immunopharma Inc (ESLA.O) is -3.11, compared to its 5-year average forward P/E of -0.52. For a more detailed relative valuation and DCF analysis to assess Estrella Immunopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.52
Current PE
-3.11
Overvalued PE
0.45
Undervalued PE
-1.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ESLA News & Events

Events Timeline

(ET)
2025-12-04
08:20:00
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II
select
2025-11-03 (ET)
2025-11-03
08:09:03
Estrella Immunopharma finishes administering the second dose group in the STARLIGHT-1 trial.
select
2025-06-05 (ET)
2025-06-05
08:25:15
Estrella Immunopharma announces additional site for STARLIGHT-1 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
08-13Benzinga
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
9.0
06-05Newsfilter
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

  • Clinical Trial Expansion: Estrella Immunopharma has activated a second clinical site at Baylor Research Institute for its STARLIGHT-1 Phase I/II trial of EB103, a CD19-Redirected ARTEMIS® T-cell therapy aimed at treating relapsed or refractory B-cell non-Hodgkin's lymphoma.

  • Therapeutic Approach: EB103 utilizes innovative ARTEMIS® technology to target and destroy CD19-positive cancer cells, representing a potential advancement in safer and more effective treatments for patients with advanced NHL.

[object Object]
Preview
4.0
06-03Benzinga
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

  • Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Estrella Immunopharma Inc (ESLA) stock price today?

The current price of ESLA is 1.93 USD — it has increased 12.21 % in the last trading day.

arrow icon

What is Estrella Immunopharma Inc (ESLA)'s business?

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

arrow icon

What is the price predicton of ESLA Stock?

Wall Street analysts forecast ESLA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESLA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Estrella Immunopharma Inc (ESLA)'s revenue for the last quarter?

Estrella Immunopharma Inc revenue for the last quarter amounts to -4.80M USD, increased 922.54 % YoY.

arrow icon

What is Estrella Immunopharma Inc (ESLA)'s earnings per share (EPS) for the last quarter?

Estrella Immunopharma Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Estrella Immunopharma Inc (ESLA)'s fundamentals?

The market is revising No Change the revenue expectations for Estrella Immunopharma, Inc. (ESLA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 83.81%.
arrow icon

How many employees does Estrella Immunopharma Inc (ESLA). have?

Estrella Immunopharma Inc (ESLA) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Estrella Immunopharma Inc (ESLA) market cap?

Today ESLA has the market capitalization of 73.27M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free